Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02387177 · ClinicalTrials.gov registry record · NA

Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype

A NA study of Neurofibromatoses, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
51
Enrollment target
1
Study location

NCT02387177 is a NA study of Neurofibromatoses that has completed, run by Massachusetts General Hospital. The registered enrollment target is 51 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02387177, a NA study of Neurofibromatoses, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

The aim of this research is to adapt the NF-specific adult version of the Skype 3RP for use with adolescents, and to test its feasibility, acceptability, and preliminary effect in improving quality of life, and in decreasing stress and psychological distress.

Conditions Studied

Interventions

  • BEHAVIORAL Stress Management Group 1
  • BEHAVIORAL Stress Management Group 2

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2015-01
Est. Completion 2017-12
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02387177

The ClinicalTrials.gov registry entry for NCT02387177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neurofibromatoses appearing as the primary indexed condition, and to 2 interventions - of which Stress Management Group 1 is the first listed.

NCT02387177 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02387177 about?

NCT02387177 is a clinical study titled "Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype". The aim of this research is to adapt the NF-specific adult version of the Skype 3RP for use with adolescents, and to test its feasibility, acceptability, and preliminary effect in improving quality of life, and in decreasing stress and psychological distress.

What is the current status of trial NCT02387177?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2015-01. Estimated completion is 2017-12.

What conditions does trial NCT02387177 study?

This clinical trial studies the following conditions: Neurofibromatoses.

What interventions are being tested in trial NCT02387177?

The interventions under investigation include: Stress Management Group 1 (BEHAVIORAL), Stress Management Group 2 (BEHAVIORAL).

Who is sponsoring clinical trial NCT02387177?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02387177 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurofibromatoses

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.